Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q1 2021 · 10-Q
Revenue$1.45M$1.45M+75.2% vs Q1 2020 Net Income-$18.46M-$18.46MN/M vs Q1 2020 EPS Diluted-$2.91-$2.91N/M vs Q1 2020 Operating Income-$18,515,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Free Cash Flowderived-$11,554,000N/M Margins · derivedOperating margin-1276.0%−310.1 pt vs Q1 2020
Net margin-1272.2%−300.7 pt vs Q1 2020
ended Mar 31, 2021 · filed May 7, 2021 · 37 d after period end